VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
    Obradović, Marko ; Mrhar, Aleš ; Kos, Mitja, 1973-
    The aim of the present study was to evaluate the cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. MethodsČ ... Standard therapy was compared with alternative strategies based on UGT1A1 genotyping from the US healthcare payer perspective. Two alternative strategies (dose reduction and prophylactic use of G-CSF with prior genotyping) and standard therapy were evaluated in a decision analysis, whereas alternative regimens were consideredin discussion. The effectiveness outcome was severe neutropenia occurrence and number of life-years gained. Results & Conclusion: Genotyping in combination with a subsequent reduction of initial irinotecan dose for UGT1A1 7/7 genotype patients was cost-saving for the population of African andCaucasian origin. By contrast, UGT1A1 genotyping was not cost effective forthe population of Asian ancestry. Furthermore, the prophylactic use of G-CSFs in UGT1A1 7/7 genotype patients was not cost effective in any population group. Finally, the application of a 3-weekly high-dose treatment regimen with a 20% reduced dosage compared with the low-dose weekly irinotecanregimen in patients with UGT1A1 7/7 genotype was less expensive and is more convenient for the patient.
    Vir: Pharmacogenomics. - ISSN 1462-2416 (vol. 9, no. 5, 2008, str. 539-549)
    Vrsta gradiva - članek, sestavni del
    Leto - 2008
    Jezik - angleški
    COBISS.SI-ID - 2324593

vir: Pharmacogenomics. - ISSN 1462-2416 (vol. 9, no. 5, 2008, str. 539-549)
loading ...
loading ...
loading ...

Vnos na polico